TLPH Stock Overview
A specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Talphera, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.71 |
| 52 Week High | US$1.61 |
| 52 Week Low | US$0.61 |
| Beta | 0.31 |
| 11 Month Change | -32.34% |
| 3 Month Change | -21.52% |
| 1 Year Change | 10.39% |
| 33 Year Change | -94.78% |
| 5 Year Change | -97.99% |
| Change since IPO | -99.22% |
Recent News & Updates
Recent updates
AcelRx: The Catalogue Of Catalysts - Including A Big One That Will Do Investors Well
Aug 18AcelRx Pharmaceuticals: Finally, Plan B
Jun 06AcelRx Pharmaceuticals: Making Sense Of The Q4 Numbers
Mar 16AcelRx Pharmaceuticals: The Fog Is Getting Thicker
Jan 14AcelRx: Battered And Bruised But Ready For Recovery In 2022
Jan 05AcelRx Pharmaceuticals: Is Wayne Gretzky Right Or The Puck?
Oct 02AcelRx Pharmaceuticals: How The Licensing Agreements Could Become A Shot In The Arm
Jul 27FDA agrees with AcelRx to update promotional materials for Dsuvia
Jun 17Shareholders May Find It Hard To Justify Increasing AcelRx Pharmaceuticals, Inc.'s (NASDAQ:ACRX) CEO Compensation For Now
Jun 11
AcelRx Pharmaceuticals: A Bullish View In 3 Song Titles
May 31Shareholder Returns
| TLPH | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -20.6% | -3.8% | -1.0% |
| 1Y | 10.4% | 9.8% | 30.3% |
Return vs Industry: TLPH exceeded the US Pharmaceuticals industry which returned 8.7% over the past year.
Return vs Market: TLPH underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| TLPH volatility | |
|---|---|
| TLPH Average Weekly Movement | 15.6% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TLPH's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TLPH's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 15 | Vince Angotti | talphera.com |
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.
Talphera, Inc. Fundamentals Summary
| TLPH fundamental statistics | |
|---|---|
| Market cap | US$11.39m |
| Earnings (TTM) | -US$15.64m |
| Revenue (TTM) | US$281.00k |
42.7x
P/S Ratio-0.8x
P/E RatioIs TLPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TLPH income statement (TTM) | |
|---|---|
| Revenue | US$281.00k |
| Cost of Revenue | US$5.55m |
| Gross Profit | -US$5.26m |
| Other Expenses | US$10.37m |
| Earnings | -US$15.64m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.92 |
| Gross Margin | -1,873.67% |
| Net Profit Margin | -5,565.48% |
| Debt/Equity Ratio | 51.3% |
How did TLPH perform over the long term?
See historical performance and comparison